194 related articles for article (PubMed ID: 35068168)
1. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
[No Abstract] [Full Text] [Related]
2. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.
Thach A; Kirson N; Zichlin ML; Dieye I; Pappert E; Williams GR
J Health Econ Outcomes Res; 2021; 8(2):82-92. PubMed ID: 35178465
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
5. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
6. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
[No Abstract] [Full Text] [Related]
7. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
8. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
9. Levodopa Inhalation Powder: A Review in Parkinson's Disease.
Paik J
Drugs; 2020 Jun; 80(8):821-828. PubMed ID: 32319076
[TBL] [Abstract][Full Text] [Related]
10. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
11. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.
Jost WH; Kulisevsky J; LeWitt PA
J Neural Transm (Vienna); 2023 Jun; 130(6):821-826. PubMed ID: 37087697
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
[TBL] [Abstract][Full Text] [Related]
13. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
Grosset DG; Dhall R; Gurevich T; Kassubek J; Poewe WH; Rascol O; Rudzinska M; Cormier J; Sedkov A; Oh C
Parkinsonism Relat Disord; 2020 Feb; 71():4-10. PubMed ID: 31927343
[TBL] [Abstract][Full Text] [Related]
14. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
15. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
16. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.
Lipp MM; Batycky R; Moore J; Leinonen M; Freed MI
Sci Transl Med; 2016 Oct; 8(360):360ra136. PubMed ID: 27733560
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
20. On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Olanow CW; Poewe W; Rascol O; Stocchi F
Mov Disord; 2021 Oct; 36(10):2244-2253. PubMed ID: 34363424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
